Assessment of hs-CRP level in centrally obese patients
European Journal of Molecular & Clinical Medicine,
2022, Volume 9, Issue 8, Pages 3460-3463
Abstract
Obesity comorbidities include coronary heart disease, hypertension and stroke, certain types of cancer, non-insulin-dependent diabetes mellitus, gallbladder disease, dyslipidaemia, osteoarthritis and gout, and pulmonary diseases, including sleep apnoea. The present study was conducted to assess hs-CRP in centrally obese patients.Materials & Methods: 145 subjects of both genders were subjected to assessment of blood pressure, body weight, height and body mass index (BMI). Measurement of hs-CRP was performed.
Results: Out of 145 patients, males were 80 and females were 65. The mean height in males was 5.8 feet and in females was 5.4 feet, weight was 78.2 kgs and in females was 67.5 kgs. The mean BMI was 25.4 Kg/m2 in males and 23.6 Kg/m2 in females. The difference was significant (P< 0.05). The mean CRP level in normal subjects was 3.4 mg/dl, in overweight was 6.5 mg/dl, in class I obese was 8.2 mg/dl, in class II obese was 12.1 mg/dl and in class III obese was 14.3 mg/dl. The difference was significant (P< 0.05).
Conclusion: hs-CRP in centrally obese patients was significantly high as compared to normal subjects.
- Article View: 14
- PDF Download: 26